-

Half-Year Liquidity Contract Statement for MEDINCELL

PARIS--(BUSINESS WIRE)--Regulatory News:

Under the liquidity contract entered into between MEDINCELL (Paris:MEDCL) and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2022:

- 47,218 shares
- € 102,733.69

- Number of executions on buy side on semester: 1,082
- Number of executions on sell side on semester: 912
- Traded volume on buy side on semester: 125,950 shares for € 916,263.63
- Traded volume on sell side on semester: 94,893 shares for € 704,766.60

As a reminder :

  • the following resources appeared on the last half year statement on 31 December 2021 on the liquidity account:

- 16,161 shares
- € 314,681.05

- Number of executions on buy side on semester: 627
- Number of executions on sell side on semester: 708
- Traded volume on buy side on semester: 66,789 shares for € 624,998.07
- Traded volume on sell side on semester: 69,983 shares for € 669,428.60

  • the following resources appeared on the liquidity account when the activity started:

- 0 shares
- € 200,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

o0o

  Buy Side     Sell Side  
  Number of
executions
Number of
shares
Traded volume
in EUR
  Number of
executions
Number of
shares
Traded volume
in EUR
Total

1,082

125,950

916,263.63

 

912

94,893

704,766.60

03/01/2022

2

187

1,911.14

 

24

2,089

21,474.92

04/01/2022

28

3,374

34,617.24

 

9

1,000

10,610.00

05/01/2022

15

1,843

18,153.55

 

6

1,000

10,000.00

06/01/2022

12

980

9,564.80

 

8

393

3,863.19

07/01/2022

15

2,000

19,040.00

 

27

1,291

12,574.34

10/01/2022

22

2,000

18,880.00

 

-

-

-

11/01/2022

10

401

3,717.27

 

7

401

3,761.38

12/01/2022

3

400

3,728.00

 

1

33

308.88

13/01/2022

15

1,600

14,640.00

 

6

500

4,590.00

14/01/2022

14

1,078

9,680.44

 

-

-

-

17/01/2022

14

1,122

9,896.04

 

1

200

1,818.00

18/01/2022

11

800

6,928.00

 

3

600

5,232.00

19/01/2022

10

1,400

11,970.00

 

1

200

1,720.00

20/01/2022

10

1,001

8,488.48

 

8

600

5,130.00

21/01/2022

12

1,799

15,453.41

 

22

1,525

13,282.75

24/01/2022

12

1,800

15,120.00

 

3

59

510.94

25/01/2022

6

448

3,700.48

 

4

400

3,332.00

26/01/2022

17

952

7,796.88

 

13

1,200

9,924.00

27/01/2022

19

2,800

22,008.00

 

8

800

6,424.00

28/01/2022

9

800

6,328.00

 

1

45

360.00

31/01/2022

13

1,200

9,552.00

 

16

1,355

10,934.85

01/02/2022

-

-

-

 

25

2,800

23,296.00

02/02/2022

1

200

1,700.00

 

7

727

6,295.82

03/02/2022

12

1,200

10,200.00

 

7

471

4,074.15

04/02/2022

22

2,424

20,143.44

 

9

909

7,690.14

07/02/2022

-

-

-

 

15

1,820

15,506.40

08/02/2022

12

1,601

13,480.42

 

4

216

1,874.88

09/02/2022

1

200

1,680.00

 

2

28

236.88

10/02/2022

-

-

-

 

16

2,046

17,697.90

11/02/2022

12

1,200

10,380.00

 

-

-

-

14/02/2022

20

2,500

20,975.00

 

-

-

-

15/02/2022

6

800

6,600.00

 

8

1,000

8,400.00

16/02/2022

12

1,145

9,595.10

 

8

800

6,824.00

17/02/2022

17

2,016

16,128.00

 

2

14

116.20

18/02/2022

27

3,116

24,117.84

 

1

127

1,010.92

21/02/2022

16

1,199

8,992.50

 

1

200

1,552.00

22/02/2022

14

1,267

9,084.39

 

32

3,200

24,288.00

23/02/2022

7

600

4,590.00

 

3

400

3,112.00

24/02/2022

27

3,533

25,154.96

 

-

-

-

25/02/2022

2

400

2,848.00

 

13

1,600

11,728.00

28/02/2022

17

2,600

18,148.00

 

6

842

6,011.88

01/03/2022

6

1,000

7,100.00

 

4

380

2,747.40

02/03/2022

24

2,605

17,687.95

 

1

200

1,392.00

03/03/2022

15

2,195

14,223.60

 

3

400

2,764.00

04/03/2022

12

1,400

8,568.00

 

-

-

-

07/03/2022

20

2,500

14,300.00

 

-

-

-

08/03/2022

-

-

-

 

10

1,313

8,140.60

09/03/2022

-

-

-

 

20

2,887

18,938.72

10/03/2022

8

794

5,161.00

 

1

1

6.56

11/03/2022

3

203

1,307.32

 

15

1,289

8,623.41

14/03/2022

3

400

2,736.00

 

7

710

4,927.40

15/03/2022

12

1,201

8,010.67

 

6

601

4,026.70

16/03/2022

-

-

-

 

12

1,400

9,674.00

17/03/2022

6

1,200

8,304.00

 

3

200

1,420.00

18/03/2022

6

600

4,050.00

 

9

399

2,725.17

21/03/2022

2

106

720.80

 

5

601

4,140.89

22/03/2022

1

1

6.95

 

13

1,609

11,456.08

23/03/2022

22

1,740

12,127.80

 

1

1

7.23

24/03/2022

5

600

4,110.00

 

2

400

2,792.00

25/03/2022

7

1,200

8,424.00

 

16

2,600

18,928.00

28/03/2022

2

200

1,460.00

 

16

2,600

19,552.00

29/03/2022

4

800

6,016.00

 

12

1,082

8,353.04

30/03/2022

8

800

5,952.00

 

8

723

5,473.11

31/03/2022

9

1,000

7,500.00

 

2

200

1,552.00

01/04/2022

2

160

1,174.40

 

13

1,428

10,738.56

04/04/2022

8

600

4,470.00

 

30

3,876

30,504.12

05/04/2022

-

-

-

 

20

2,381

20,214.69

06/04/2022

20

1,800

15,012.00

 

-

-

-

07/04/2022

10

1,403

11,392.36

 

9

1,001

8,268.26

08/04/2022

10

1,518

12,189.54

 

3

201

1,648.20

11/04/2022

3

401

3,175.92

 

30

4,401

37,276.47

12/04/2022

10

1,300

10,985.00

 

18

2,000

17,340.00

13/04/2022

8

900

7,596.00

 

3

61

528.87

14/04/2022

6

930

7,877.10

 

22

2,588

22,670.88

19/04/2022

10

1,303

11,297.01

 

12

1,368

12,147.84

20/04/2022

59

9,117

60,810.39

 

-

-

-

21/04/2022

11

1,800

10,836.00

 

-

-

-

22/04/2022

23

3,000

17,040.00

 

-

-

-

25/04/2022

9

1,000

5,300.00

 

13

1,800

10,080.00

26/04/2022

7

1,200

7,008.00

 

13

1,400

8,358.00

27/04/2022

12

1,600

8,960.00

 

-

-

-

28/04/2022

5

800

4,384.00

 

3

200

1,150.00

29/04/2022

4

601

3,371.61

 

8

1,000

5,670.00

02/05/2022

9

1,112

6,193.84

 

5

600

3,450.00

03/05/2022

2

341

1,950.52

 

5

600

3,516.00

04/05/2022

5

800

4,640.00

 

3

401

2,389.96

05/05/2022

5

211

1,211.14

 

1

140

820.40

06/05/2022

8

989

5,577.96

 

-

-

-

09/05/2022

5

800

4,536.00

 

3

400

2,340.00

10/05/2022

7

800

4,376.00

 

7

400

2,212.00

11/05/2022

5

400

2,240.00

 

9

986

5,639.92

12/05/2022

5

566

3,169.60

 

1

97

558.72

13/05/2022

5

400

2,188.00

 

3

200

1,120.00

16/05/2022

1

200

1,080.00

 

-

-

-

17/05/2022

3

201

1,073.34

 

4

601

3,299.49

18/05/2022

1

1

5.47

 

5

801

4,565.70

19/05/2022

6

600

3,396.00

 

7

903

5,228.37

20/05/2022

-

-

-

 

44

750

4,380.00

23/05/2022

8

750

4,297.50

 

1

250

1,450.00

24/05/2022

7

750

4,312.50

 

-

-

-

25/05/2022

5

250

1,425.00

 

2

86

495.36

26/05/2022

3

500

2,800.00

 

-

-

-

27/05/2022

6

501

2,765.52

 

3

251

1,395.56

30/05/2022

4

250

1,375.00

 

5

516

2,905.08

31/05/2022

7

1,001

5,525.52

 

1

1

5.69

01/06/2022

3

500

2,735.00

 

2

255

1,417.80

02/06/2022

9

870

4,689.30

 

1

1

5.47

03/06/2022

3

381

2,023.11

 

1

100

536.00

06/06/2022

-

-

-

 

1

250

1,340.00

07/06/2022

1

200

1,068.00

 

7

850

4,573.00

08/06/2022

3

200

1,068.00

 

3

350

1,890.00

09/06/2022

4

149

795.66

 

2

263

1,409.68

10/06/2022

5

501

2,655.30

 

1

1

5.40

13/06/2022

3

400

2,088.00

 

9

1,186

6,297.66

14/06/2022

5

500

2,645.00

 

23

2,895

15,806.70

15/06/2022

3

501

2,695.38

 

12

1,750

9,660.00

16/06/2022

3

500

2,760.00

 

5

597

3,379.02

17/06/2022

8

1,000

5,440.00

 

-

-

-

20/06/2022

7

999

5,314.68

 

5

500

2,680.00

21/06/2022

1

38

201.40

 

1

100

536.00

22/06/2022

3

712

3,730.88

 

14

1,500

8,145.00

23/06/2022

1

250

1,360.00

 

6

500

2,765.00

24/06/2022

5

461

2,521.67

 

6

409

2,261.77

27/06/2022

3

290

1,568.90

 

-

-

-

28/06/2022

2

251

1,340.34

 

6

461

2,503.23

29/06/2022

6

850

4,505.00

 

3

250

1,350.00

30/06/2022

11

1,010

5,282.30

 

5

500

2,630.00

 

Contacts

MEDINCELL

MEDINCELL

BOURSE:MEDCL

Release Versions

Contacts

MEDINCELL

More News From MEDINCELL

Medincell: The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in Adults

TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Regulatory News:  Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Medincell (Euronext: MEDCL), today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for olanzapine long-acting injectable (TEV-‘749) for the treatment of schizophrenia in adults. TEV-‘749 aims to address treatment adherence in real-world settings and contri...

Medincell - UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year‑on‑Year

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY U.S. net sales reached $63 million in Q1 2026, representing a 62% increase from $39 million in Q1 2025 and a 15% increase from $55 million in Q4 2025. Medincell receives mid‑ to high‑single-digit royalties on UZEDY net sales and is eligible for up to $105M in commercial milestone payments, subject to the achievement of annual sa...

Degroof Petercam Initiates Medincell’s Coverage with a “Buy” Recommendation

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the initiation of coverage by Degroof Petercam, a leading European investment bank with strong healthcare expertise. Christophe Douat, CEO of Medincell, said: “Broader analyst coverage in Europe and the United States reflects the growing transatlantic interest in Medincell and...
Back to Newsroom